Implementation of performance based contracting in Malaysia

Performance based contracting (PBC) has been used for several years in other countries.This procurement approach however can be considered new in Malaysia.In the past, this type of procurement was popular in lines such as production, maintenance, military, supply and service businesses.This paper studies about the challenges, benefits, tools, strategies and aspects of PBC that can be adopted from other countries and relates it for the purpose of improving Malaysian construction industry.Using outcomes from a series of open-ended interviews as well as from theoretical literature review, this paper also explores both success and failure factors of PBC and suggests a way in which it can be used in Malaysian construction industry. Finding from interviews indicates that Malaysian status of PBC implementation is not as expected. People are aware of PBC but the implementation is not well enough and it relates to the challenges from external and internal causes.However, tools like financial management and services improvement from PBC as well as encouragement and spread of awareness can be used to improve Malaysian construction industry

In-situ surface functionalization of superparamagnetic reduced graphene oxide – Fe3O4 nanocomposite via Ganoderma lucidum extract for targeted cancer therapy application

A superparamagnetic graphene-based magnetite nanocomposite (rGO-Fe3O4) was synthesized via a simple in-situ chemical approach. This rGO-Fe3O4 nanocomposite can be used as a drug carrier that is able to be guided by external magnetic fields to the specific site of interest for targeted drug delivery application to treat cancer. Ganoderma lucidum extract (GL) was employed, which successfully stabilized the rGO-Fe3O4 via hydrogen bonding and resulted in enhancement of water dispersibility and stability of the prepared nanocomposite, while Pluronic F-127 (PF) was introduced to reduce the overall cytotoxicity. The presence of both GL and PF on the surface of nanocomposite was successfully validated by cyclic voltammetry (CV). Quercetin (Que), a naturally-available polyphenolic flavonoid with anti-cancer properties was utilized to study the potential of rGO-Fe3O4-GL-PF for controlled drug delivery application. The loading capacity of Que on rGO-Fe3O4-GL-PF was determined to be 11 wt% through UV–visible spectroscopy. The Que was loaded on rGO plane via π-π stacking and hydrophobic interaction, which was validated through CV. Furthermore, the in-vitro cytotoxicity of the synthesized nanocomposite showed obvious cytotoxicity toward A549 cells due to the anti-cancer properties of GL which has high potential to be developed into a targeted drug delivery carrier for cancer therapeutics

Synergistic effects of catalytic co-pyrolysis Chlorella vulgaris and polyethylene mixtures using artificial neuron network: Thermodynamic and empirical kinetic analyses

The catalytic pyrolysis of Chlorella vulgaris, high-density polyethylene (Pure HDPE) and, their binary mixtures were conducted to analyse the kinetic and thermodynamic performances from 10 to 100 K/min. The kinetic parameters were computed by substituting the experimental and ANN predicted data into these iso-conversional equations and plotting linear plots. Among all the iso-conversional models, Flynn-Wall-Ozawa (FWO) model gave the best prediction for kinetic parameters with the lowest deviation error (2.28–12.76%). The bifunctional HZSM-5/LS catalysts were found out to be the best catalysts among HZSM-5 zeolite, natural limestone (LS), and bifunctional HZSM-5/LS catalyst in co-pyrolysis of binary mixture of Chlorella vulgaris and HDPE, in which the Ea of the whole system was reduced from range 144.93–225.84 kJ/mol (without catalysts) to 75.37–76.90 kJ/mol. With the aid of artificial neuron network and genetic algorithm, an empirical model with a mean absolute percentage error (MAPE) of 51.59% was developed for tri-solid state degradation system. The developed empirical model is comparable to the thermogravimetry analysis (TGA) experimental values alongside the other empirical model proposed in literatur

Overexpression of Nrdp1 in the Heart Exacerbates Doxorubicin-Induced Cardiac Dysfunction in Mice

BACKGROUND: Cardiac cell death and generation of oxidative stress contribute to doxorubicin (DOX)-induced cardiac dysfunction. E3 ligase Nrdp1 plays a critical role in the regulation of cell apoptosis, inflammation and production of reactive oxygen species (ROS), which may contribute to heart failure. However, the role of Nrdp1 in DOX-induced cardiac injury remains to be determined. METHODS AND RESULTS: We examined the effect of Nrdp1 overexpression with DOX treatment in rat neonatal cardiomyocytes and mouse heart tissue. Cardiomyocytes were infected with adenovirus containing GFP (Ad-GFP), Nrdp1 wild-type (Ad-Nrdp1) or the dominant-negative form of Nrdp1 (Ad-Dn-Nrdp1), then treated with DOX for 24 hr. DOX treatment increased cell death and apoptosis, with Ad-Nrdp1 infection enhancing these actions but Ad-Dn-Nrdp1 infection attenuating these effects. Furthermore, 5 days after a single injection of DOX (20 mg/kg, intraperitoneally), Nrdp1 transgenic mice (TG) showed decreased cardiac function and increased apoptosis, autophagy and oxidative stress as compared with wild-type (WT) mice (P<0.01). Survival rate was significantly lower in Nrdp1 TG mice than in WT mice 10 days after DOX injection (P<0.01). CONCLUSIONS/SIGNIFICANCE: These results were associated with decreased activation of Akt, extracellular signal-regulated kinase 1/2 (ERK1/2) and signal transducer and activator of transcription 3 (STAT3) signaling pathways. Nrdp1 may be a key mediator in the development of cardiac dysfunction after DOX treatment and associated with inhibition of Akt, ERK1/2 and STAT3. Nrdp1 may be a new therapeutic target in protecting against the cardiotoxic effects of DOX

Diverse Applications of Nanomedicine

The design and use of materials in the nanoscale size range for addressing medical and health-related issues continues to receive increasing interest. Research in nanomedicine spans a multitude of areas, including drug delivery, vaccine development, antibacterial, diagnosis and imaging tools, wearable devices, implants, high-throughput screening platforms, etc. using biological, nonbiological, biomimetic, or hybrid materials. Many of these developments are starting to be translated into viable clinical products. Here, we provide an overview of recent developments in nanomedicine and highlight the current challenges and upcoming opportunities for the field and translation to the clinic. \ua9 2017 American Chemical Society

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer (p < 4.28 × 10−15), including three risk variants that have yet to be reported. From a polygenic risk score (PRS) model, derived to assess the cumulative effect of risk variants at 8q24, men in the top 1% of the PRS have a 4-fold (95%CI = 3.62–4.40) greater risk compared to the population average. These 12 variants account for ~25% of what can be currently explained of the familial risk of prostate cancer by known genetic risk factors. These findings highlight the overwhelming contribution of germline variation at 8q24 on prostate cancer risk which has implications for population risk stratification

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

Prostate cancer is a highly heritable disease with large disparities in incidence rates across ancestry populations. We conducted a multiancestry meta-analysis of prostate cancer genome-wide association studies (107,247 cases and 127,006 controls) and identified 86 new genetic risk variants independently associated with prostate cancer risk, bringing the total to 269 known risk variants. The top genetic risk score (GRS) decile was associated with odds ratios that ranged from 5.06 (95% confidence interval (CI), 4.84-5.29) for men of European ancestry to 3.74 (95% CI, 3.36-4.17) for men of African ancestry. Men of African ancestry were estimated to have a mean GRS that was 2.18-times higher (95% CI, 2.14-2.22), and men of East Asian ancestry 0.73-times lower (95% CI, 0.71-0.76), than men of European ancestry. These findings support the role of germline variation contributing to population differences in prostate cancer risk, with the GRS offering an approach for personalized risk prediction